ANUHPHR91.70

Anuh Pharma Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAHCLWANBURYZIMLABBAJAJHCARETHEMISMEDLINCOLNVALIANTLABSIGACHIMcap ₹919 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations159.5198.1186.5372.4197.2202.1193.8
Other Income0.91.43.44.44.1-1.33.1
Total Income160.5199.5189.9376.7201.3200.9196.9
Expenses
+ Cost of Materials Consumed118.7137.9123.9255.4114.3140.7160.0
+ Purchases of Stock-in-Trade14.510.926.544.931.52.84.1
+ Changes in Inventories-12.7-0.42.2-3.15.57.7-15.8
+ Employee Benefit Expense5.56.86.313.06.96.37.4
+ Finance Costs0.30.00.20.30.10.10.0
+ Depreciation & Amortisation2.22.82.55.43.03.02.4
+ Other Expenses18.724.217.340.022.224.721.9
Total Expenses147.2182.3178.9355.9183.5185.3180.0
EBITDA14.818.710.322.216.819.916.3
EBIT12.615.97.816.813.816.913.9
Profit
PBT before Exceptional Items13.317.311.020.917.815.516.9
Pretax Income13.317.311.020.917.815.516.9
+ Current Tax3.25.42.55.35.04.84.1
+ Deferred Tax-0.3-0.60.2-0.3-0.6-0.91.4
Tax Expense2.94.82.75.04.43.85.5
Net Income10.312.58.315.913.511.711.4
+ Net Income — Continuing Ops10.312.58.315.913.511.711.4
+ Other Comprehensive Income0.00.1-0.10.00.5-0.3-0.0
Total Comprehensive Income10.412.68.215.913.911.411.4
Per Share
Basic EPS2.062.491.661.591.341.171.14
Diluted EPS2.062.491.661.591.341.171.14
Other Comprehensive Income — detail
+ Other Comprehensive Income0.1-0.10.00.5-0.3-0.0
+ Items NOT to be Reclassified to P&L0.00.1-0.10.00.6-0.4-0.0
+ Tax on Items NOT to be Reclassified0.0-0.00.00.2-0.1-0.0
+ Tax on Items NOT to be Reclassified — alt tag0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations2.062.491.661.591.341.171.14
Diluted EPS — Continuing Operations2.062.491.661.591.341.171.14
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period24.828.344.8
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit39.049.733.975.245.950.945.5
Gross Margin %24.4725.0718.1620.2023.2825.1823.48
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)13.317.311.020.917.815.516.9
Net Income Adj (tax-effected)10.312.58.315.913.511.711.4
EPS Adj2.062.491.661.591.341.171.14
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.005.005.005.00
Paid Up Equity Capital25.125.125.150.150.150.150.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.